Direct Healthcare Professional Communication (Rote-Hand-Brief) on Natpar 100 micrograms/dose powder and solvent for solution for injection of the company Takeda: Expected supply shortage from July 1st, 2022
2022.05.09
Active substance: Parathyroid hormone
Takeda informs of an expected supply shortage for the medicinal product Natpar 100 micrograms/dose strength due to manufacturing challenges. The duration of the shortage is unknown but is expected to last at least 6 months. There is a possibility that the 75 micrograms/dose strength may be similarly affected by a shortage later in 2022. Therefore, the company published the recommendations described in the Direct Healthcare Professional Communication.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN